Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

1044403

USP

Atenolol

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

(±)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, 4-[2′-Hydroxy-3′-(isopropylamino)propoxy]phenylacetamide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C14H22N2O3
Número de CAS:
29122-68-7
Peso molecular:
266.34
Número MDL:
MFCD00057645
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
329749076
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

atenolol

fabricante / nombre comercial

USP

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

Clave InChI

METKIMKYRPQLGS-UHFFFAOYSA-N

Información sobre el gen

human ... ADRB1(153)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Atenolol USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Atenolol Tablets
  • Atenolol Injection
  • Atenolol Compounded Oral Suspension
  • Atenolol and Chlorthalidone Tablets
  • Atenolol Compounded Oral Suspension, Veterinary
  • Levobunolol Hydrochloride

Nota de análisis

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Y0001089

Atenolol for system suitability, European Pharmacopoeia (EP) Reference Standard

A1340000

Atenolol, European Pharmacopoeia (EP) Reference Standard

BP370

Atenolol impurity standard, British Pharmacopoeia (BP) Reference Standard

BP492

Atenolol, British Pharmacopoeia (BP) Reference Standard

1044367

Atenolol Related Compound F, United States Pharmacopeia (USP) Reference Standard

1044265

Atenolol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1044254

Atenolol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1044276

Atenolol Related Compound C, United States Pharmacopeia (USP) Reference Standard

1044298

Atenolol Related Compound E, United States Pharmacopeia (USP) Reference Standard

1044287

Atenolol Related Compound D, United States Pharmacopeia (USP) Reference Standard

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Los clientes también vieron

Slide 1 of 1

1 of 1

Sodium dichloroisocyanurate dihydrate 98.0% (AT)

Sigma-Aldrich

35915

Sodium dichloroisocyanurate dihydrate

Sripal Bangalore et al.
The American journal of medicine, 127(10), 939-953 (2014-06-15)
Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcome
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing
H Sakurai et al.
Japanese circulation journal, 64(11), 893-896 (2000-12-08)
Cardiogenic shock developed in a 72-year-old Japanese woman during combination therapy with verapamil and atenolol for recurrent supraventricular arrhythmia. She had coronary atherosclerosis, liver cirrhosis and bradycardia-tachycardia syndrome. Despite of the high-dose catecholamines and counterpulsation, she progressively deteriorated. Bolus administration
Atenolol: pharmacokinetic/dynamic aspects of comparative developmental toxicity.
Sonia A Tabacova et al.
Reproductive toxicology (Elmsford, N.Y.), 16(1), 1-7 (2002-04-06)
Laura M Kuyper et al.
The Canadian journal of cardiology, 30(5 Suppl), S47-S53 (2014-04-23)
Previous reviews have shown that β-blocker use for the treatment of hypertension without compelling indications was associated with increased risk of stroke in the elderly. It remains unclear whether this increased risk was driven by the type of β-blocker. We
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico